Overview

FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

Status:
Completed
Trial end date:
2012-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab lengthens the time a patient remains free of leukemia symptoms.
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche
Collaborators:
Biogen
Genentech, Inc.
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Rituximab